Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 65 clinical trials
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy

The current study aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies taken starting from 35 +/- 4 days after the initiation of neoadjuvant chemotherapy.

adjuvant therapy
breast cancer
invasive breast cancer
cancer
  • 28 views
  • 28 May, 2021
  • 36 locations
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

n the present study the neoadjuvant approach with the anti-HER2 trastuzumab and pertuzumab combined with carboplatin and paclitaxel will be used to compare the Event-Free Survival (EFS) in regimens with and without atezolizumab. Following the neoadjuvant part of the study, after surgery all patients will continue to receive trastuzumab and …

carboplatin
cyclophosphamide
progesterone
sentinel lymph node biopsy
residual tumor
  • 17 views
  • 24 Jan, 2021
  • 51 locations
Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis

To investigate the efficacy of capecitabine combined with paclitaxel as neoadjuvant chemotherapy for gastric cancer with liver metastasis only

xeloda
metastasis
carcinoma
cancer chemotherapy
liver metastasis
  • 16 views
  • 08 Nov, 2020
  • 1 location
Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Phase II, randomized, open-label, international, multicenter study to compare efficacy of standard chemotherapy vs. letrozole plus abemaciclib as neoadjuvant therapy in HR-positive/HER2-negative high/intermediate risk breast cancer patients

  • 0 views
  • 26 Jan, 2021
  • 28 locations
Remote Ischemic Conditioning in Oncology

This is a feasibility study at a single site, Cincinnati Children's Hospital Medical Center. Patients undergoing anthracycline chemotherapy for Hodgkin disease and soft-tissue and bone sarcoma who meet eligibility requirements will be approached to participate in the study. The purpose of the study is to determine if performing remote ischemic …

  • 0 views
  • 26 Jun, 2021
  • 1 location
Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction

Cardiomyopathy is a major complication of doxorubicin (DOX) chemotherapy, and 10-21% of breast cancer patients receiving DOX experience compromised cardiac function. Recent advancements have increased cancer survivorship but it remains clinically challenging to mitigate the cardiotoxic side effects. Although there are several strategies used to reduce the occurrence and severity …

  • 4 views
  • 09 Jul, 2021
  • 1 location
Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)

This is a randomized, open-label, multicenter, phase III study comparing anthracyclines followed by taxane to anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in

breast surgery
carcinoma
core needle biopsy
primary tumor
invasive carcinoma
  • 82 views
  • 23 Jan, 2021
  • 12 locations
Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

with very limited mature B-NHL (R1 and R2 stage I and II) of substituting anthracyclines by the rituximab window without compromising survival rates. the effectiveness (event-free survival

  • 496 views
  • 16 Jun, 2021
  • 93 locations
Study for Patients With Newly Diagnosed High-risk Acute Promyelocytic Leukemia

/ATRA protocol with the addition of two doses of IDA (50% compared to standard AIDA induction) for induction because of the anticipated need of adding anthracyclines to control hyperleukocytosis and to

tretinoin
cytarabine
hysterectomy
monoclonal antibody
methotrexate
  • 0 views
  • 26 Aug, 2021
  • 8 locations
Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)

This is a prospective, single center, randomized, open-labled stage III clinical trial comparing the efficacy and safety of anthracyclin followed by weekly paclitaxel versus dose-dense anthracyclin followed by weekly paclitaxel versus dose-dense anthracyclin followed by weekly paclitaxel combined with carboplatin for high-risk, triple-negative early breast cancer.

carboplatin
epirubicin
platelet count
cancer
triple negative breast cancer
  • 20 views
  • 23 Jan, 2021
  • 1 location